Canada - TSX Venture Exchange - TSX-V:QPT - CA74836M1068 - Common Stock
The current stock price of QPT.CA is 0.035 CAD. In the past month the price decreased by -12.5%. In the past year, price increased by 16.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 432.55M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 367.23M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 178.73M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 131.79M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24 | 53.03M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 33.04M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.42M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 29.70M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.08M | ||
| MPH.CA | MEDICURE INC | N/A | 13.99M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.22M | ||
| APS.CA | APTOSE BIOSCIENCES INC | N/A | 5.69M |
Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. The company is headquartered in Edmonton, Alberta. The firm is developing products to improve the quality of life. The firm is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The firm has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The firm also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
QUEST PHARMATECH INC
4342 97 Street
Edmonton ALBERTA T6E 6S4 CA
CEO: Ragupathy Madiyalakan,
Employees: 0
Phone: 17804481400
Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. The company is headquartered in Edmonton, Alberta. The firm is developing products to improve the quality of life. The firm is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The firm has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The firm also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
The current stock price of QPT.CA is 0.035 CAD.
QPT.CA does not pay a dividend.
QPT.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on QPT.CA.
QUEST PHARMATECH INC (QPT.CA) will report earnings on 2025-12-17.
ChartMill assigns a technical rating of 1 / 10 to QPT.CA. When comparing the yearly performance of all stocks, QPT.CA is a bad performer in the overall market: 63.82% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to QPT.CA. QPT.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months QPT.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS decreased by -108.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.94% | ||
| ROE | -5.2% | ||
| Debt/Equity | 0.05 |